Research Evidence Anecdotal Efficacy Side Effects Price Dosing & Protocol Regulatory Safety Notes

Liraglutide

Liraglutide is a first-generation GLP-1 receptor agonist primarily utilized for weight management and glycemic control in type 2 diabetes. Users typically administer the peptide via subcutaneous injection at a modal dose of 1.2 mg daily, though reported usage spans from 300 µg to 6 mg per day. While the substance is well-documented for its approved indications, the broader evidence base for exploratory uses remains thin, with many potential applications lacking published results. Reported side effects are infrequent, with nausea, gastrointestinal distress, sleep disturbances, and fluid retention surfacing only occasionally in community reports.

Half-life~13 h

Data last updated August 3, 2026

Research Evidence

Evidence shape

Liraglutide carries high-tier clinical evidence, supported by extensive research primarily focused on diabetes and obesity management. With 426 registered trials and 82 blinded studies, the literature base is robust, featuring 132 distinct sponsors and significant data on metabolic outcomes. While the clinical foundation for its primary indications is substantial, the research landscape also includes over 80 exploratory or thin indications, many of which are represented by single-trial long-tail studies that lack the scale or consistent results seen in its core therapeutic applications.

Depthhow much

426 registered trials

320 completed · 130 with posted results · 22 recruiting / active · combined n=332587

Breadthhow many areas

106 indications mapped

15 with results · 81 thin / exploratory · 1 animal-only · 74 single-trial long-tail

Qualityhow rigorous

Highest tier: Phase 3

82 blinded with results · 132 distinct sponsors · AE rows aggregated from 103 trials · 44 linked publications on registered trials

Breadth and depth456 rows captured

Human

direct clinical signal

441

Animal

translational support

12

In vitro

mechanistic support

3

HighMediumLow

Source data

Every row behind the score.

456 total

RCTNCT00154401Phase 2 · 2005 · n=177 · Novo Nordisk A/S

Diabetes

tested HbA1c

result Completed; results not posted

RCTNCT00154414Phase 2 · 2005 · n=226 · Novo Nordisk A/S

Diabetes

tested HbA1c

result Completed; results not posted

RCTNCT00294723Phase 3 · 2006 · n=746 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 52

result Terminated before completion

Terminated: The trial was terminated at week 195 due to an insufficient number of subjects remaining to obtain reasonable statistical power

RCTNCT00318422Phase 3 · 2006 · n=1041 · Novo Nordisk A/S

Diabetes

tested HbA1c

result Completed; results not posted

RCTNCT00318461Phase 3 · 2006 · n=1091 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated A1c (HbA1c) at Week 26

RCTNCT00331851Phase 3 · 2006 · n=584 · Novo Nordisk A/S

Diabetes

tested HbA1c

result Completed; results not posted

RCTNCT00333151Phase 3 · 2006 · n=576 · Novo Nordisk A/S

Diabetes

tested HbA1c

result Completed; results not posted

RCTNCT00393718Phase 3 · 2006 · n=400 · Novo Nordisk A/S

Diabetes

tested Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment

result −0.5 percentage of total haemoglobin (Glycosylated Haemoglobin A1c (HbA1c) After 24 Week…)

RCTNCT00395746Phase 3 · 2006 · n=264 · Novo Nordisk A/S

Diabetes

tested Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment

RCTNCT00422058Phase 2 · 2007 · n=564 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Mean Change From Baseline in Body Weight at Week 20

result +0.2 kg (Mean Change From Baseline in Body Weight at Week 2…)

RCTNCT00518882Phase 3 · 2007 · n=467 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated A1c (HbA1c) at Week 26

result −0.3 percentage point of total HbA1c (Change in Glycosylated A1c (HbA1c) at Week 26)

RCTNCT00614120Phase 3 · 2008 · n=929 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated Haemoglobin A1c (HbA1c)

RCTNCT00620282Phase 3 · 2008 · n=49 · Novo Nordisk A/S

Diabetes

tested Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)

RCTNCT00696657Phase 2 · 2008 · n=415 · Novo Nordisk A/S

Diabetes

tested HbA1c

result −0.6 Percentage (%) of HbA1c (HbA1c)

RCTNCT00700817Phase 3 · 2008 · n=665 · Novo Nordisk A/S

Diabetes

tested Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26

RCTNCT00761540Phase 1 · 2008 · n=37 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested AUC 0-24h (last dosing day): Area under the plasma liraglutide curve from 0 to 24 hours after last dosing.

result Completed; results not posted

RCTNCT00781937Phase 3 · 2008 · n=422 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Mean Percentage Change in Fasting Body Weight From Baseline

result −6.1 percentage (Mean Percentage Change in Fasting Body Weight From…)

RCTNCT00856986Phase 3 · 2009 · n=987 · Novo Nordisk A/S

Diabetes

tested Mean Change From Randomisation in Glycosylated Haemoglobin A1c (HbA1c) at Week 26.

RCTNCT00943501Phase 1 · 2009 · n=21 · Novo Nordisk A/S

Diabetes

tested Number and type of adverse events

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT00978393Phase 1 · 2009 · n=49 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Gastric emptying measured as AUC0-300min of paracetamol postprandial concentration profiles during a standardised meal test with intake of 1.5 g paracetamol

result Completed; results not posted

RCTNCT00983021Phase 1 · 2009 · n=24 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Number and severity of adverse events, number and severity of local tolerability issues at the injection site, number and severity of hypoglycaemic episodes

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT00993304Phase 1 · 2009 · n=20 · Novo Nordisk A/S

Diabetes

tested AUC0-8h (triglyceride), the area under the triglyceride-concentration-time curve in the interval 0-8 hours following a meal with a high fat content

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT00993720Phase 2 · 2009 · n=30 · Hvidovre University Hospital

Diabetes Mellitus

tested insulin-dose

result Completed; results not posted

RCTNCT01029886Phase 3 · 2010 · n=912 · AstraZeneca

Type 2 Diabetes Mellitus

tested Change in HbA1c From Baseline to Week 26

result −0.2 percentage of total hemoglobin (Change in HbA1c From Baseline to Week 26)

RCTNCT01117350Phase 4 · 2010 · n=978 · Sanofi

Diabetes Mellitus, Type 2

tested Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period

result −2.5 percentage of participants (Percentage of Patients Whose Glycosylated Haemoglo…)

RCTNCT01128894Phase 3 · 2010 · n=841 · GlaxoSmithKline

Diabetes Mellitus, Type 2

tested Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 32

result −0.2 Percentage of HbA1c in the blood (Mean Change From Baseline in Glycosylated Hemoglob…)

RCTNCT01175473Phase 2 · 2010 · n=148 · Sanofi

Type 2 Diabetes Mellitus

tested Change From Baseline in Area Under the Plasma Glucose Concentration Curve From Time 0.5 Hours to 4.5 Hours (GLU-AUC0:30-4:30h) at Day 28

result +154 h*mg/dL (Change From Baseline in Area Under the Plasma Gluc…)

RCTNCT01179048Phase 3 · 2010 · n=9341 · Novo Nordisk A/S

Diabetes

tested Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)

result −1.9 percentage of subjects (Time From Randomisation to First Occurrence of Car…)

RCTNCT01206101Phase 2 · 2012 · n=3 · Novo Nordisk A/S

Diabetes

tested Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant

result Terminated before completion

Terminated: The decision to close the NN2211-3619 trial was based on the very low recruitment rate as well as challenges relating to trial execution and study completion.

RCTNCT01208012Phase 4 · 2010 · n=44 · ikfe-CRO GmbH

Diabetes Mellitus, Type 2

tested The difference in increase of retinal blood flow after flicker stimulation of retinal endothelial cells

result Completed; results not posted

RCTNCT012329462012 · n=30 · Indiana University

Type 2 Diabetes

tested Myocardial Glucose Uptake

RCTNCT01234649Phase 3 · 2011 · n=153 · Woman's

Gestational Diabetes Mellitus

tested Insulin Secretion-Sensitivity Index (IS-SI)

result +85.4 index (Insulin Secretion-Sensitivity Index (IS-SI))

RCTNCT01237119Phase 2 · 2010 · n=52 · University of Birmingham

NAFLD / steatotic liver disease — hepatic fat reduction

tested Liver Histological improvement

result Completed; results not posted

RCTNCT01270789Phase 3 · 2011 · n=63 · Mount Sinai Hospital, Canada

Type 2 Diabetes

tested Preservation of beta-cell function measured by Insulin Secretion-Sensitivity Index-2 (ISSI-2)

result Completed; results not posted

RCTNCT01272219Phase 3 · 2011 · n=3731 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Change From Baseline in Fasting Body Weight

result −5.4 percent change (Change From Baseline in Fasting Body Weight)

RCTNCT01272232Phase 3 · 2011 · n=846 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Change (%) From Baseline in Body Weight (Fasting)

result −3.9 percent change (Change (%) From Baseline in Body Weight (Fasting))

RCTNCT01296412Phase 3 · 2011 · n=653 · Merck Sharp & Dohme LLC

Diabetes Mellitus, Type 2

tested Change From Baseline in Hemoglobin A1c (A1C)

result −0.1 percent (Change From Baseline in Hemoglobin A1c (A1C))

RCTNCT01319240Phase 1 · 2011 · n=24 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested The area under insulin degludec concentration-time curve

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01336023Phase 3 · 2011 · n=1663 · Novo Nordisk A/S

Diabetes

tested Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.

RCTNCT013636092011 · n=50 · Amsterdam UMC, location VUmc

Obesity

tested food-stimuli related neuronal activity in reward and satiety circuits as represented by BOLD fMRI signal change from baseline (%)

result Completed; results not posted

RCTNCT01373450Phase 1 · 2011 · n=12 · Merck Sharp & Dohme LLC

Type 2 Diabetes Mellitus

tested Change From Baseline in Time-weighted Average of Glucose Measured by Area Under the Curve (AUC) After a Single Dose of Oxyntomodulin (OXM)

result −16.3 mg/dL (Change From Baseline in Time-weighted Average of G…)

Small sample; effect at the edge of clinical significance.

RCTNCT01388361Phase 3 · 2011 · n=413 · Novo Nordisk A/S

Diabetes

tested Change From Baseline in HbA1c (%) (Glycosylated Haemoglobin)

RCTNCT01392573Phase 3 · 2011 · n=413 · Novo Nordisk A/S

Diabetes

tested Change From Baseline in HbA1c (Glycosylated Haemoglobin)

RCTNCT013928982012 · n=50 · Radboud University Medical Center

Type 2 Diabetes Mellitus

tested Body weight change (measured body weight at 26 weeks minus baseline body weight)

result In progress (unknown)

RCTNCT01394341Phase 4 · 2011 · n=40 · Bo Feldt-Rasmussen

Type 2 Diabetes Mellitus

tested Plasma liraglutide concentration (pmol/L)

result Completed; results not posted

RCTNCT01399645Phase 2 · 2011 · n=35 · Centre hospitalier de l'Université de Montréal (CHUM)

NAFLD / steatotic liver disease — hepatic fat reduction

tested To determine liver fat fraction evolution induced by liraglutide and insulin

result Completed; results not posted

RCTNCT01425580Phase 2 · 2012 · n=62 · Thomas Nystrom

Congestive Heart Failure

tested Left ventricle longitudinal function and/or functional reserve during rest and/or after exercise using tissue Doppler echocardiography

result Completed; results not posted

RCTNCT014519052011 · n=12 · University Hospital, Gentofte, Copenhagen

Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI

tested Changes in PASI and DLQI

result In progress (unknown)

RCTNCT014600692011 · n=20 · Annesofie Faurschou

Psoriasis

tested PASI (psoriasis area and severity index)

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT014693512012 · n=34 · University of Aarhus

Alzheimers Disease

tested PIB PET scan

result Completed; results not posted

RCTNCT014726402011 · n=240 · Flyvbjerg, Allan, DMSc

Hyperglycemia

tested Change in Left ventricular function from visit 1 to week 24, measured by Ecco

result Completed; results not posted

RCTNCT01473953Phase 1 · 2011 · n=31 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Number of Treatment Emergent Adverse Events (TEAEs)

RCTNCT01505673Phase 4 · 2012 · n=71 · Ildiko Lingvay

Type 2 Diabetes Mellitus

tested Glycemic Control Measured by HbA1c

result −1.0 Percent HbA1c (Glycemic Control Measured by HbA1c)

RCTNCT01507272Phase 1 · 1999 · n=34 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested AUC (area under the curve)

result Completed; results not posted

RCTNCT01507285Phase 1 · 1999 · n=24 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Area under the Curve

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01507311Phase 1 · 1999 · n=11 · Novo Nordisk A/S

Diabetes

tested Insulin secretory burst mass

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01508858Phase 1 · 2006 · n=21 · Novo Nordisk A/S

Diabetes

tested AUC of ethinylestradiol

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01508897Phase 1 · 2004 · n=22 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Area under the Curve (AUC) (0-t)

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01508923Phase 2 · 2001 · n=17 · Novo Nordisk A/S

Diabetes

tested 24-hour glucose profiles after three fixed meals

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01508949Phase 2 · 2001 · n=35 · Novo Nordisk A/S

Diabetes

tested Change in weight

result Completed; results not posted

RCTNCT01509742Phase 1 · 2001 · n=19 · Novo Nordisk A/S

Diabetes

tested Area under the Curve (AUC) glucagon

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01511159Phase 1 · 2001 · n=32 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Ratio of the areas under the plasma NN 90-1170 curves

result Completed; results not posted

RCTNCT01511172Phase 2 · 2002 · n=145 · Novo Nordisk A/S

Diabetes

tested Fasting plasma/serum glucose

result Completed; results not posted

RCTNCT01511185Phase 1 · 2001 · n=20 · Novo Nordisk A/S

Diabetes

tested AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01511198Phase 2 · 2001 · n=223 · Novo Nordisk A/S

Diabetes

tested Body weight

result Completed; results not posted

RCTNCT01511692Phase 1 · 2005 · n=43 · Novo Nordisk A/S

Diabetes

tested The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10

result Completed; results not posted

RCTNCT01512108Phase 3 · 2012 · n=363 · Novo Nordisk A/S

Diabetes

tested Incidence of Treatment Emergent Adverse Events (AEs)

result +30.0 Events/100 years of patient exposure (Incidence of Treatment Emergent Adverse Events (AE…)

RCTNCT01513525Phase 1 · 2007 · n=21 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Area under the Curve (AUC) of liraglutide for each injection site

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01514487Phase 1 · 2005 · n=24 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Area under the Curve (0-t)

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01515553Phase 1 · 2007 · n=22 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Area under the curve (0-t)

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01515579Phase 1 · 2006 · n=22 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Area under the curve (0-t)

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01515592Phase 1 · 2006 · n=24 · Novo Nordisk A/S

Diabetes

tested Adverse events

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01516255Phase 1 · 2006 · n=64 · Novo Nordisk A/S

Diabetes

tested Maximum time-matched mean difference between the baseline subtracted QTci intervals

result Completed; results not posted

RCTNCT01516476Phase 2 · 2011 · n=2 · Hoffmann-La Roche

Diabetes Mellitus Type 2

tested Change in hemoglobin A1c (HA1c)

result Terminated before completion

RCTNCT01517555Phase 1 · 2006 · n=18 · Novo Nordisk A/S

Diabetes

tested Area under the curve of paracetamol

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01518101Phase 4 · 2012 · n=62 · Novartis Pharmaceuticals

Type 2 Diabetes

tested Proportion of patients preferring each treatment regimen

result Completed; results not posted

RCTNCT01518166Phase 1 · 2006 · n=70 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Area under the curve of atorvastatin

result Completed; results not posted

RCTNCT01536665Phase 1 · 2012 · n=45 · Novo Nordisk A/S

Diabetes

tested Geometric mean glucagon concentration during hypoglycaemia (nadir glucose (target 2.5 mmol/L) )

result Completed; results not posted

RCTNCT01541215Phase 3 · 2012 · n=135 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c (Glycosylated Haemoglobin)

result −1.1 Percentage of HbA1c (Change in HbA1c (Glycosylated Haemoglobin))

RCTNCT01550653Phase 1 · 2012 · n=40 · University of Luebeck

Pharmacokinetic / healthy volunteer studies

tested Change from Baseline in the immediate and delayed recall of a declarative memory task (word list recall) at time points indicated in "time frame" section.

result Completed; results not posted

RCTNCT01557166Phase 3 · 2012 · n=359 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Change From Baseline in Apnoea-hypopnoea Index (AHI)

result −6.1 events/hour (Change From Baseline in Apnoea-hypopnoea Index (AH…)

RCTNCT01558271Phase 3 · 2012 · n=492 · Eli Lilly and Company

Type 2 Diabetes Mellitus

tested Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks

result −1.5 percentage of HbA1c (Change From Baseline in Glycosylated Hemoglobin (H…)

RCTNCT01562678Phase 4 · 2012 · n=28 · Beth Israel Deaconess Medical Center

Diabetes

tested Change Between Highly Desirable vs. Less Desirable Food Cues in the Effect Size of Cortical Activation During Food Visualization

result −0.9 z-scores of activation in cortex (Change Between Highly Desirable vs. Less Desirable…)

Small sample; effect at the edge of clinical significance.

RCTNCT01572740Phase 3 · 2012 · n=257 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 16

result −1.3 percentage of glycosylated haemoglobin (Change in Glycosylated Haemoglobin (HbA1c) From Ba…)

RCTNCT01592279Phase 4 · 2012 · n=124 · Hadassah Medical Organization

Uncontrolled Type 1 Diabetic Patients

tested The primary end point is the change in HbA1C relative to baseline after 3 months treatment with liraglutide in uncontrolled type 1 diabetic patients. The expected change is 1% reduction from baseline.

result In progress (unknown)

RCTNCT01593137Phase 4 · 2012 · Fundación Fernández-Cruz

Type 2 Diabetes

tested assess the effect of treatment with liraglutide compared to glimepiride, as add-on to metformin, for one year on circulating levels of EPCs in patients with type 2 diabetes poorly controlled.

result Withdrawn before enrolment

Withdrawn: Lack of patients with the criteria established in the protocol.

RCTNCT01595789Phase 4 · 2012 · n=41 · Haugaard, Steen Bendix, M.D., DMSc

Coronary Artery Disease

tested Beta-cell function

result Completed; results not posted

RCTNCT01596504Phase 2 · 2012 · n=142 · Sanofi

Type 2 Diabetes Mellitus

tested Change From Baseline to Day 56 in Plasma Glucose Corrected Area Under The Plasma Concentration-Time Curve (AUC) From Time 0.5 Hours to 4.5 Hours

RCTNCT01597531Phase 4 · 2012 · n=1 · East Carolina University

Type 2 Diabetes

tested Type 2 diabetes remission

result Terminated before completion

Terminated: Difficulty recruiting patients

RCTNCT01610934Phase 2 · 2012 · n=15 · University Hospital, Gentofte, Copenhagen

Maturity-onset Diabetes of the Young

tested Fasting Plasma Glucose

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01612468Phase 4 · 2012 · n=100 · Steno Diabetes Center Copenhagen

Diabetes Mellitus, Type 1

tested Change in HbA1c

result Completed; results not posted

RCTNCT01615978Phase 1 · 2003 · n=15 · Novo Nordisk A/S

Diabetes

tested 24-hour profiles of serum calcitonin

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01617434Phase 3 · 2012 · n=451 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26

result −1.2 percentage of glycosylated haemoglobin (Change in Glycosylated Haemoglobin (HbA1c) From Ba…)

RCTNCT01618162Phase 3 · 2012 · n=435 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated Haemoglobin (HbA1c)

result −1.0 percentage of glycosylated haemoglobin (Change in Glycosylated Haemoglobin (HbA1c))

RCTNCT01620463Phase 1 · 2002 · n=32 · Novo Nordisk A/S

Diabetes

tested Body weight

result Completed; results not posted

RCTNCT01620476Phase 1 · 2003 · n=24 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Area under the plasma liraglutide curve

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01620489Phase 3 · 2012 · n=279 · Novo Nordisk A/S

Diabetes

tested Estimated Mean From the Statistical Model and Standard Deviation From Observed Data For Change From Baseline to Week 26 in HbA1c (%) (Glycosylated Haemoglobin)

result −0.7 percentage (%) (Estimated Mean From the Statistical Model and Stan…)

RCTNCT01624259Phase 3 · 2012 · n=599 · Eli Lilly and Company

Type 2 Diabetes

tested Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

result +0.1 percentage of glycosylated hemoglobin (Change From Baseline to 26 Weeks Endpoint in Glyco…)

RCTNCT01628445Phase 3 · 2012 · n=52 · University of Manitoba

Type 2 Diabetes

tested Change in A1c

result Terminated before completion

Terminated: Error made by local pharmacy caused mixed randomization of 20 participants

RCTNCT01638260Phase 4 · 2012 · n=22 · Maastricht University Medical Center

Type 2 Diabetes Mellitus

tested Change in HbA1c from baseline and end of treatment (26 weeks) and end of follow-up (52 weeks)

result Terminated before completion

Terminated: Terminated because of insufficient number of subjects included.

RCTNCT01654120Phase 4 · 2011 · n=37 · Mountain Diabetes and Endocrine Center

Diabetes Mellitus, Type II

tested Change from baseline in HbA1c at six months

result Completed; results not posted

RCTNCT01658501Phase 2 · 2012 · n=593 · PhaseBio Pharmaceuticals Inc.

Type 2 Diabetes Mellitus

tested Evaluation of dose response of Glymera as measured as the change from baseline in HbA1c after 20 weeks of dosing with Glymera compared to placebo and active comparator

result Completed; results not posted

RCTNCT01664247Phase 3 · 2012 · n=346 · Novo Nordisk A/S

Diabetes

tested Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%)

result −0.9 percentage of glycosylated haemoglobin (Change From Baseline in Glycosylated Haemoglobin (…)

RCTNCT01664676Phase 4 · 2012 · n=11 · University of Aarhus

Type 2 Diabetes Mellitus

tested Glomerular Filtration Rate (51Cr-EDTA plasma clearance)

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01676116Phase 3 · 2012 · n=438 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)

result −1.0 percentage of glycosylated haemoglobin (Change in Glycosylated Haemoglobin (HbA1c) From Ba…)

RCTNCT01695109Phase 4 · 2010 · n=16 · Medical University of Vienna

Healthy Human Male Subjects

tested Food intake at an ad libitum buffet

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01722227Phase 3 · 2012 · University at Buffalo

Type 1 Diabetes

tested Mean weekly blood glucose concentrations.

result Withdrawn before enrolment

Withdrawn: No Funding Received from ADA

RCTNCT01722240Phase 3 · 2012 · n=69 · University at Buffalo

Type 1 Diabetes

tested HbA1c (%)

result +0.4 Percent of Hemoglobin (%) (HbA1c (%))

RCTNCT01722266Phase 3 · 2012 · n=72 · University at Buffalo

Type 1 Diabetes

tested Change in Mean Weekly Glucose Concentrations

result −11.0 mg/dl (Change in Mean Weekly Glucose Concentrations)

RCTNCT01725126Phase 2 · 2013 · n=53 · GlaxoSmithKline

Obesity

tested Number of Participants With Any Adverse Event (AE), Serious Adverse Event (SAE) or Death During Part A

result +7.0 Participants (Number of Participants With Any Adverse Event (AE)…)

RCTNCT01733758Phase 3 · 2013 · n=494 · GlaxoSmithKline

Diabetes Mellitus, Type 2

tested Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

result −0.1 Percentage of HbA1c in the blood (Mean HbA1c at Baseline, Week 24, and Change From B…)

RCTNCT01739049Phase 4 · 2012 · n=42 · Universiti Kebangsaan Malaysia Medical Centre

Binge Eating Behaviour

tested Reduction in binge eating scale score

result Completed; results not posted

RCTNCT017409212011 · n=39 · Royal Devon and Exeter NHS Foundation Trust

Type 2 Diabetes

tested change of baseline skin maximum hyperaemia at 4 months

result Completed; results not posted

RCTNCT01744236Phase 4 · 2013 · n=70 · Amsterdam UMC, location VUmc

Type 2 Diabetes

tested Changes from baseline following infusion of GLP-1RA (acute effects) and the changes from baseline following 12-week treatment with GLP-1RA or DPP-4i (long-term effects) on resting heart rate variability, as derived from electrocardiographic measurements.

result Completed; results not posted

RCTNCT01753362Phase 3 · 2012 · n=84 · University at Buffalo

Type 1 Diabetes

tested HbA1c

result +0.2 percent (HbA1c)

RCTNCT01755416Phase 2 · 2013 · n=18 · Albert Einstein College of Medicine

Type 1 Diabetes

tested Blood Glucose Measures in Subjects on Closed Loop With Insulin and Liraglutide, Compared to the Closed Loop With Insulin Alone

result −15.1 mg/dl (Blood Glucose Measures in Subjects on Closed Loop …)

Small sample; effect at the edge of clinical significance.

RCTNCT01755572Phase 4 · 2013 · n=22 · Mount Sinai Hospital, Canada

Type 2 Diabetes

tested Change in plasma ANP level at 1 Day

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01761318Phase 4 · 2013 · n=50 · Leiden University Medical Center

NAFLD / steatotic liver disease — hepatic fat reduction

tested Stroke volume

result Completed; results not posted

RCTNCT01779362Phase 3 · 2013 · n=267 · RISE Study Group

Prediabetes

tested ß-cell Response Measured by Hyperglycemic Clamp

result +0.1 nmol/L (ß-cell Response Measured by Hyperglycemic Clamp)

RCTNCT01782261Phase 2 · 2012 · n=15 · Medical University of Graz

Type 1 Diabetes

tested Increase of regulatory FOXP3+ T cells

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01784965Phase 3 · 2009 · n=69 · Stanford University

Pre-diabetes

tested Change in Weight Reported at 14 Weeks

result −3.5 kg (Change in Weight Reported at 14 Weeks)

RCTNCT01785043Phase 4 · 2013 · n=13 · Anna Cruceta

DIABETES Mellitus Type 2 Not Well Controlled

tested Assess the effects on endothelial function of a three month treatment with Liraglutide compared to Sitagliptin.

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01787916Phase 4 · 2013 · n=15 · CHU de Quebec-Universite Laval

Type 1 Diabetes

tested Assessment of Changes in Glycemic Control by HbA1c.

result +0.1 percentage of HbA1c (Assessment of Changes in Glycemic Control by HbA1c…)

Small sample; effect at the edge of clinical significance.

RCTNCT01789086Phase 1 · 2013 · n=21 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Number of treatment emergent adverse events (TEAEs)

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01790308Phase 4 · 2013 · n=100 · Sun Yat-sen University

Diabetes Mellitus, Type 2

tested the percentage of the patients who maintain glucose control 1 year after short intensive therapy

result In progress (unknown)

RCTNCT01794143Phase 3 · 2013 · n=7850 · GRADE Study Group

Type 2 Diabetes

tested Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication

RCTNCT01795248Phase 4 · 2012 · n=105 · Tina Vilsboll

Gestational Diabetes Mellitus

tested Change in glucose tolerance

result Completed; results not posted

RCTNCT01800968Phase 2 · 2013 · n=300 · Duke University

Acute Heart Failure

tested Global Ranking of Predefined Events

result −10.2 rank (Global Ranking of Predefined Events)

RCTNCT01836523Phase 3 · 2013 · n=1398 · Novo Nordisk A/S

Diabetes

tested Change From Baseline in HbA1c (Glycosylated Haemoglobin)

result −0.1 percentage of glycosylated haemoglobin (Change From Baseline in HbA1c (Glycosylated Haemog…)

RCTNCT01843075Phase 2 · 2014 · n=204 · Imperial College London

Alzheimer's Disease

tested The change in cerebral glucose metabolic rate

result In progress (unknown)

RCTNCT01845259Phase 2 · 2013 · n=103 · Psychiatric Centre Rigshospitalet

Impaired Glucose Tolerance Associated With Drugs

tested Glucose tolerance

result In progress (unknown)

RCTNCT01847313Phase 3 · 2013 · n=20 · Karl Neff

Diabetic Kidney Disease

tested MCP-1:Creatinine Ratio in Urine

result +3.6 ng/mmol (MCP-1:Creatinine Ratio in Urine)

Small sample; effect at the edge of clinical significance.

RCTNCT01870297Phase 1 · 2013 · n=72 · Eli Lilly and Company

Type 2 Diabetes Mellitus

tested Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

result ±0.0 participants (Number of Participants With One or More Serious Ad…)

RCTNCT01879917Phase 2 · 2014 · n=65 · Hvidovre University Hospital

Diabetes Mellitus, Type 1

tested Beta-cell function

result Completed; results not posted

RCTNCT01899430Phase 4 · 2011 · n=32 · University Medical Centre Ljubljana

PCOS

tested The main outcome was change in body weight.

result Completed; results not posted

RCTNCT01907854Phase 4 · 2013 · n=407 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c (Glycosylated Haemoglobin)

result −0.6 percentage of glycosylated haemoglobin (Change in HbA1c (Glycosylated Haemoglobin))

RCTNCT01911468Phase 4 · 2011 · n=36 · University Medical Centre Ljubljana

PCOS

tested The main outcome was change in body weight.

result Completed; results not posted

RCTNCT01916174Phase 1 · 2013 · n=50 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Area under the serum IDeg concentration time curve after single dose

result Completed; results not posted

RCTNCT01917656Phase 4 · 2014 · n=343 · Novo Nordisk A/S

Diabetes

tested Change in Fructosamine From Start of Ramadan to End of Ramadan

result +1.7 umol/L (Change in Fructosamine From Start of Ramadan to En…)

RCTNCT01919489Phase 4 · 2014 · n=273 · Emory University

Type 2 Diabetes

tested Glycemic Control at Hospital Discharge and 6 Months Follow up

result −0.1 % (mmol/mol) (Glycemic Control at Hospital Discharge and 6 Month…)

RCTNCT01931982Phase 4 · 2013 · n=20 · Bispebjerg Hospital

Type 2 Diabetes

tested Change in coronary flow reserve (CFR)

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT01937598Phase 3 · 2013 · n=16 · Michael A. Nauck

Type 2 Diabetes

tested Incremental Area Under the Plasma Glucose (BG) Concentration-time Profile (AUC)

result +121 [mg*min/dL] (Incremental Area Under the Plasma Glucose (BG) Con…)

Small sample; effect at the edge of clinical significance.

RCTNCT01952145Phase 3 · 2013 · n=557 · Novo Nordisk A/S

Diabetes

tested Change From Baseline in HbA1c (Glycosylated Haemoglobin)

result −0.7 Percentage (%) (Change From Baseline in HbA1c (Glycosylated Haemog…)

RCTNCT01966978Phase 4 · 2014 · n=157 · University of Texas Southwestern Medical Center

Diabetes Mellitus, Type 2

tested Mean Change From Randomization in A1c at Week 26

result +0.7 Percentage of glycosylated hemoglobin (Mean Change From Randomization in A1c at Week 26)

RCTNCT01973231Phase 4 · 2013 · n=404 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated Haemoglobin (HbA1c) From Baseline

result −0.6 Percent (%) glycosylated haemoglobin (Change in Glycosylated Haemoglobin (HbA1c) From Ba…)

RCTNCT01982630Phase 1 · 2013 · n=87 · Merck Sharp & Dohme LLC

Diabetes Mellitus

tested Number of Participants Experiencing Adverse Events (AEs) in Part 1

result −3.0 Participants (Number of Participants Experiencing Adverse Events…)

RCTNCT020013632013 · n=90 · Chen Wei Ren, MD

Acute Myocardial Infarction

tested the salvage index measured by cardiac magnetic resonance

result In progress (unknown)

RCTNCT02008682Phase 4 · 2013 · n=368 · Novo Nordisk A/S

Diabetes

tested Change From Baseline in Glycosylated Haemoglobin (HbA1c)

result −0.7 Percent (%) glycosylated haemoglobin (Change From Baseline in Glycosylated Haemoglobin (…)

RCTNCT02014740Phase 4 · 2014 · n=100 · University of Miami

Type 2 Diabetes

tested Echocardiographic Epicardial Fat Thickness

result +2.2 mm (Echocardiographic Epicardial Fat Thickness)

RCTNCT02016846Phase 3 · 2014 · n=36 · Rabin Medical Center

Glucocorticoid Induced Hyperglycemia

tested Glucose levels 2 hours after 75 gr OGTT

result In progress (unknown)

RCTNCT020363722014 · n=150 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Diabetes Mellitus Type II

tested Median glucose

result Completed; results not posted

RCTNCT02043054Phase 3 · 2013 · n=90 · University of Leicester

Type 2 Diabetes Mellitus

tested Change in peak early diastolic strain rate measured by cardiac MRI

result Completed; results not posted

RCTNCT02055014Phase 4 · 2013 · n=72 · Sandwell & West Birmingham Hospitals NHS Trust

Type 2 Diabetes

tested Glycated haemoglobin (HbA1c)

result In progress (unknown)

RCTNCT02057172Phase 2 · 2014 · n=254 · Hanmi Pharmaceutical Company Limited

Type 2 Diabetes

tested Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks

result Completed; results not posted

RCTNCT02059564Phase 1 · 2013 · n=44 · Hanmi Pharmaceutical Company Limited

Diabetes Mellitus

tested PK profile of acetaminophen

result In progress (unknown)

RCTNCT02060383Phase 4 · 2014 · n=249 · Novartis Pharmaceuticals

Cushing's Disease

tested Change in HbA1c From Randomization to Approximately 16 Weeks

RCTNCT02072096Phase 4 · 2014 · n=192 · Eli Lilly and Company

Diabetes Mellitus, Type 2

tested Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia

result Terminated before completion

Terminated: The trial was terminated per protocol because of lack of feasibility.

RCTNCT02073929Phase 4 · 2014 · n=72 · Jens Faber

Polycystic Ovary Syndrome

tested Change in Endogenous Thrombin Potential (ETP)

result −48.5 nMolar x minutes (Change in Endogenous Thrombin Potential (ETP))

RCTNCT02092896Phase 3 · 2013 · n=40 · Hvidovre University Hospital

Diabetes

tested Change from baseline in HbA1c (glycosylated haemoglobin)

result Completed; results not posted

RCTNCT02098395Phase 3 · 2014 · n=835 · Novo Nordisk A/S

Diabetes

tested Change From Baseline in Glycosylated Haemoglobin (HbA1c)

result −0.2 Percent (%) glycosylated haemoglobin (Change From Baseline in Glycosylated Haemoglobin (…)

RCTNCT02100475Phase 3 · 2014 · n=31 · Novo Nordisk A/S

Diabetes

tested Change From Baseline in HbA1c (Glycosylated Haemoglobin)

RCTNCT02109315Phase 1 · 2014 · Anna Cruceta

Type 1 Diabetes Mellitus

tested Endothelial dysfunction (Flow mediated dilation): Endothelial function is assessed measuring flow-mediated vasodilation (FMD) of the brachial artery.

result Withdrawn before enrolment

Withdrawn before enrolment; no public reason provided.

RCTNCT02113332Phase 2 · 2013 · n=124 · Vastra Gotaland Region

Type 2 Diabetes Mellitus

tested Change in HbA1c from baseline to week 24.

result Completed; results not posted

RCTNCT021380452014 · n=39 · Aalborg University Hospital

Diabetes Mellitus, Type 1

tested RIII withdrawal reflex activity (using standard electromyography)

result Completed; results not posted

RCTNCT02140983Phase 1 · 2013 · n=41 · Stanford University

Insulin Resistance

tested Cognitive Outcomes

result Completed; results not posted

RCTNCT02147925Phase 4 · 2014 · n=75 · Sun Yat-sen University

NAFLD / steatotic liver disease — hepatic fat reduction

tested Intrahepatic lipids (IHL)

result Completed; results not posted

RCTNCT02187250Phase 4 · 2014 · n=45 · University Medical Centre Ljubljana

PCOS

tested The main outcome was change in body weight.

result Completed; results not posted

RCTNCT02205528Phase 2 · 2014 · n=108 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c

result Completed; results not posted

RCTNCT02207348Phase 1 · 2014 · n=24 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Area under the liraglutide plasma concentration time curve from 0 to last quantifiable observation (tz) after single dose

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT02231658Phase 1 · 2015 · n=109 · Profil Institut für Stoffwechselforschung GmbH

Diabetes Mellitus

tested Change from baseline (week -1) in the number of reflux episodes

result Terminated before completion

Terminated: Too challenging to recruit appropriate participants at an acceptable speed.

RCTNCT02235961Phase 1 · 2014 · n=163 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Number of treatment emergent adverse events recorded

result Completed; results not posted

RCTNCT02284230Phase 2 · 2014 · Bo Feldt-Rasmussen

Kidney Failure, Chronic

tested Plasma glucose during oral glucose tolerance test at week 26

result Withdrawn before enrolment

Withdrawn: Inability to recruit participants

RCTNCT02292290Phase 4 · 2011 · n=99 · University of Leicester

Type 2 Diabetes

tested Composite

result Completed; results not posted

RCTNCT02298192Phase 3 · 2014 · n=420 · Novo Nordisk A/S

Diabetes

tested Change From Baseline in HbA1c

RCTNCT02299388Phase 4 · 2014 · n=11 · Tulane University School of Medicine

Diabetes Mellitus, Non-Insulin-Dependent

tested Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors.

result +0.6 mm/Hg (Change in Systolic Blood Pressure as Measured by A…)

Small sample; effect at the edge of clinical significance.

RCTNCT02315001Phase 2 · 2014 · n=26 · King's College London

Ischaemic Heart Disease

tested Change in rate pressure product at 0.1 mV ST-segment depression

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT023248422014 · n=45 · The University of Texas Health Science Center at San Antonio

Type 2 Diabetes Mellitus

tested HbA1c at 4 Months

RCTNCT02344186Phase 4 · 2014 · n=12 · Temple University

Type 2 Diabetes

tested Changes in unfolded protein response markers

result In progress (unknown)

RCTNCT02351232Phase 2 · 2015 · n=44 · Hvidovre University Hospital

Type 1 Diabetes

tested Change in HbA1c

result Completed; results not posted

RCTNCT02403284Phase 4 · 2013 · n=97 · Phoenix VA Health Care System

Insulin Resistance

tested Whole Body Insulin Sensitivity (insulin suppression test)

result Completed; results not posted

RCTNCT02408705Phase 2 · 2015 · n=14 · Medical University of Graz

Type 1 Diabetes Mellitus

tested Area under the curve of the endogenous glucose production from (=EGP) from begin of the hypoglycaemic clamp 5.5 mmol/L period until the end of recovery period (4.0 mmol/L), calculated from stable isotope labelled plasma glucose

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT02417103Phase 3 · 2011 · n=2 · Universitätsklinikum Hamburg-Eppendorf

Obesity

tested weight reduction

result Terminated before completion

Terminated: Recruiting failure

RCTNCT02420262Phase 3 · 2015 · n=506 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c (Glycosylated Haemoglobin)

RCTNCT02443155Phase 2 · 2015 · n=308 · Novo Nordisk A/S

Diabetes

tested Area Under the Concentration-time Curve (AUC) 0-4h of Mixed Meal Tolerance Test (MMTT) Stimulated C-peptide at Week 54 Relative to Baseline

result +0.3 Ratio of AUC (Area Under the Concentration-time Curve (AUC) 0-4h…)

RCTNCT02453711Phase 2 · 2015 · n=957 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Relative Change in Body Weight (%)

result −5.5 Percentage (%) of body weight (Relative Change in Body Weight (%))

RCTNCT02461589Phase 2 · 2015 · n=706 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c (Glycosylated Haemoglobin)

result −0.5 percentage of glycosylated haemoglobin (Change in HbA1c (Glycosylated Haemoglobin))

RCTNCT02472717Phase 2 · 2015 · University Health Network, Toronto

Psoriatic Arthritis

tested The change in the proportion of patients achieving an ACR 20% improvement response in patients with psoriatic arthritis receiving liraglutide for 12 weeks compared to placebo

result Withdrawn before enrolment

Withdrawn before enrolment; no public reason provided.

RCTNCT02473809Phase 4 · 2015 · n=60 · University of Aarhus

Diabetes Complications

tested Change in collagen I cross-linked C-terminal telopeptide measured in serum

result Completed; results not posted

RCTNCT02483299Phase 4 · 2014 · n=40 · University Medical Centre Ljubljana

PCOS

tested Change in body weight

result Completed; results not posted

RCTNCT02488057Phase 4 · 2016 · n=360 · Ohio State University

Pre-Diabetes

tested Beta Cell Function

result Completed; results not posted

RCTNCT024901762015 · n=50 · Chinese PLA General Hospital

Heart Failure

tested a change in cardiac output measured by pulse indicator continuous cardiac output (PiCCO) technology

result In progress (unknown)

RCTNCT02492763Phase 2 · 2015 · n=176 · Merck Sharp & Dohme LLC

Type II Diabetes Mellitus

tested Change From Baseline in Hemoglobin A1C (A1C) at Week 12

result −1.0 Percent (Change From Baseline in Hemoglobin A1C (A1C) at We…)

RCTNCT02501161Phase 3 · 2016 · n=1012 · Novo Nordisk A/S

Diabetes

tested Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification

RCTNCT02501850Phase 4 · 2014 · n=40 · Hospital Universitari Vall d'Hebron Research Institute

Diabetes Mellitus Type 2

tested Change in blood levels of Lipoprotein (a) (Lp(a))

result In progress (unknown)

RCTNCT02503943Phase 4 · 2015 · n=90 · Third Affiliated Hospital of Third Military Medical University

Type 2 Diabetes

tested Blood Pressure change

result In progress (unknown)

RCTNCT02505334Phase 3 · 2015 · n=635 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated Haemoglobin (HbA1c) (Week 26)

result −0.4 Percentage (%) of HbA1c (Change in Glycosylated Haemoglobin (HbA1c) (Week 2…)

RCTNCT025071282015 · n=190 · Chen Wei Ren, MD

Acute ST-segment Elevation Myocardial Infarction

tested a change in the prevalence of no-reflow

result In progress (unknown)

RCTNCT02518945Phase 3 · 2015 · n=26 · University at Buffalo

Type 1 Diabetes Mellitus

tested Absolute Change After 12 Weeks From Baseline in Mean HbA1c With Addition of Dapagliflozin Compared to Placebo.

result −0.7 % HbA1c (Absolute Change After 12 Weeks From Baseline in Me…)

Small sample; effect at the edge of clinical significance.

RCTNCT02527200Phase 3 · 2015 · n=56 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks

result ±0.0 SDS score (Change in Body Mass Index (BMI) Standard Deviation…)

RCTNCT02527993Phase 4 · 2015 · n=11 · Zealand University Hospital

Hypoglycemia

tested Changes in blood glucose (mmol/L) assessed by continuous glucose monitoring (CGM).

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT02545738Phase 4 · 2015 · n=32 · Steno Diabetes Center Copenhagen

Diabetic Kidney Disease

tested Change in albuminuria

result Completed; results not posted

RCTNCT02584582Phase 2 · 2015 · n=10 · Hvidovre University Hospital

Type 1 Diabetes

tested Glucagon concentration (postprandial)

result In progress (unknown)

RCTNCT02607306Phase 3 · 2015 · n=819 · Novo Nordisk A/S

Diabetes

tested Change From Baseline in HbA1c (Glycosylated Haemoglobin) Tested for Non-inferiority of IDegLira vs IDeg and Superiority of IDegLira vs Lira

RCTNCT02611232Phase 2 · 2015 · n=42 · University of Oulu

Type 1 Diabetes

tested FPIR (first phase insulin response)

result In progress (unknown)

RCTNCT02617654Phase 2 · 2015 · n=18 · Per-Ola Carlsson

Type 1 Diabetes

tested The effect of 52 weeks of treatment with liraglutide 1.8 mg/day, compared to placebo, on stimulated C-peptide concentrations in patients with long-standing type 1 diabetes and residual insulin production

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT02638805Phase 3 · 2015 · n=136 · Intarcia Therapeutics

Diabetes Mellitus, Type 2

tested Number (percentage) and severity of treatment-emergent adverse events (TEAEs) of nausea and/or vomiting

result Completed; results not posted

RCTNCT02647944Phase 2 · 2015 · n=40 · Mayo Clinic

Obesity

tested Gastric Emptying of Solids Half-time (T1/2) at 5 Weeks

result +63.0 minutes (Gastric Emptying of Solids Half-time (T1/2) at 5 W…)

RCTNCT02650206Phase 1 · 2015 · n=56 · Stanford University

Diabetes Mellitus, Type 2

tested Macrophage polarization: % M2 macrophages in adipose tissue and peripheral blood according to positivity for cell surface markers (measured by flow cytometry).

result Completed; results not posted

RCTNCT02655770Phase 4 · 2016 · n=40 · Rigshospitalet, Denmark

Diabetes Mellitus Type 2

tested Change in diastolic properties as assessed by CMR.

result Completed; results not posted

RCTNCT02660047Phase 4 · 2015 · n=51 · Leiden University Medical Center

NAFLD / steatotic liver disease — hepatic fat reduction

tested Stroke volume

result Completed; results not posted

RCTNCT02686177Phase 4 · 2016 · n=50 · Assistance Publique - Hôpitaux de Paris

Type 2 Diabetes

tested Difference of ANGPTL4 concentration at 4 weeks of treatment from baseline in Liraglutide and control group

result Completed; results not posted

RCTNCT02696148Phase 1 · 2016 · n=24 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Number of treatment emergent adverse events

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT02717858Phase 1 · 2016 · n=52 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Maximum postprandial gallbladder ejection fraction (GBEFmax)

result Completed; results not posted

RCTNCT02730377Phase 4 · 2016 · n=1991 · Novo Nordisk A/S

Diabetes

tested Time to Inadequate Glycaemic Control

result +44.0 Weeks (Time to Inadequate Glycaemic Control)

RCTNCT02765399Phase 4 · 2015 · n=23 · Helsinki University Central Hospital

Type 2 Diabetes

tested Change in Liver Fat Content

result −1.3 fat % (Change in Liver Fat Content)

Small sample; effect at the edge of clinical significance.

RCTNCT02773368Phase 3 · 2016 · n=420 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c (Glycosylated Haemoglobin)

RCTNCT027770732016 · n=43 · University at Buffalo

Type 1 Diabetes

tested Difference in Ketone Bodies Formation After Single Dose of Liraglutide and Dapagliflozin

result −0.2 mM (Difference in Ketone Bodies Formation After Single…)

RCTNCT027831962016 · n=14 · Tel Aviv University

Type 2 Diabetes

tested Clock Gene expression

result In progress (unknown)

RCTNCT02787551Phase 3 · 2016 · n=514 · Sanofi

Type 2 Diabetes Mellitus

tested Change From Baseline in Glycated Hemoglobin (HbA1c) to Week 26: Core Period

RCTNCT02832999Phase 4 · 2016 · n=14 · Yaounde Central Hospital

Type 2 Diabetes Mellitus

tested Insulin sentivity

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT02863419Phase 3 · 2016 · n=711 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c (Week 26)

result −1.0 Percentage of HbA1c (Change in HbA1c (Week 26))

RCTNCT02870231Phase 1 · 2016 · n=187 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Number of treatment emergent adverse events

result Completed; results not posted

RCTNCT028794092016 · n=150 · Weill Cornell Medical College in Qatar

Diabetes Mellitus Type 2

tested Determination of the variability of HbA1c (by measurement of standard deviation of HbA1c) between the 2 diabetes treatment thresholds

result In progress (active-not-recruiting)

RCTNCT02889510Phase 3 · 2016 · n=76 · Lecube, Albert, M.D.

Type 2 Diabetes

tested Changes From Baseline on Measurements of Respiratory Function Defined by Forced Expiratory Volume in 1 Second (FEV1)

result −0.2 % (FEV1) (Changes From Baseline on Measurements of Respirato…)

RCTNCT02898506Phase 2 · 2016 · n=13 · University of Oulu

Type 1 Diabetes

tested FPIR (1+3min serum insulin level after iv glucose infusion)

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT02905864Phase 4 · 2016 · n=150 · Henrik Gudbergsen

Osteoarthritis

tested Change in body weight

result Completed; results not posted

RCTNCT02908087Phase 2 · 2016 · n=13 · University of Oulu

Type 1 Diabetes

tested Serum C-peptide AUC

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT02909933Phase 4 · 2015 · n=30 · University Medical Centre Ljubljana

Polycystic Ovary Syndrome

tested The main outcome was change in body weight.

result Completed; results not posted

RCTNCT02910570Phase 4 · 2016 · n=150 · Parker Research Institute

Osteoarthritis, Knee

tested Change in advanced glycation end products in the skin

result Completed; results not posted

RCTNCT02911818Phase 4 · 2016 · n=150 · University of Pennsylvania

Obesity

tested Percent Change in Baseline Weight

result −1.5 percent change (Extension Study Primary Outcome: Percent Change in…)

RCTNCT02911948Phase 3 · 2016 · n=210 · Novo Nordisk A/S

Diabetes

tested Change in Glycosylated Haemoglobin (HbA1c)

result −1.3 Percentage of HbA1c (Change in Glycosylated Haemoglobin (HbA1c))

RCTNCT02918279Phase 3 · 2016 · n=251 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Change in BMI SDS (Week 0, Week 56)

result −0.2 SDS score (Change in BMI SDS (Week 0, Week 56))

RCTNCT02928614Phase 4 · 2016 · n=150 · Henrik Gudbergsen

Osteoarthritis

tested Change in collagen II degradation fragment α-C2M

result Completed; results not posted

RCTNCT02928679Phase 4 · 2016 · n=150 · Henrik Gudbergsen

Osteoarthritis

tested Change in the degree of inflammation in the knee-joint (DCE-MRI)

result Completed; results not posted

RCTNCT029302652016 · n=400 · Chinese PLA General Hospital

Ischemic Cardiomyopathy

tested main adverse cardiovascular events

result In progress (unknown)

RCTNCT02931383Phase 4 · 2016 · n=150 · Henrik Gudbergsen

Osteoarthritis

tested Change in the degree of inflammation in the knee-joint (Greyscale-score)

result Completed; results not posted

RCTNCT02944500Phase 4 · 2016 · n=28 · Beth Israel Deaconess Medical Center

Obesity

tested BOLD response to food cues

result In progress (active-not-recruiting)

RCTNCT02953665Phase 2 · 2017 · n=63 · Cedars-Sinai Medical Center

Parkinson Disease

tested Change in Unified Parkinson's Disease Rating Scale (UPDRS Part III Motor Examination) During "OFF" Time From Baseline to the End of Double-Blind Maintenance Period

result +2.7 units on a scale (Change in Unified Parkinson's Disease Rating Scale…)

RCTNCT02960659Phase 1 · 2017 · n=24 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Type 2 Diabetes

tested Change in Absolute Gluconeogenesis From Baseline to 12 Weeks

result −0.1 mg/kg LBM/min (Change in Absolute Gluconeogenesis From Baseline t…)

Small sample; effect at the edge of clinical significance.

RCTNCT02963922Phase 3 · 2017 · n=396 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Change in Body Weight (%)

result −4.5 Percentage change (Change in Body Weight (%))

RCTNCT02963935Phase 3 · 2017 · n=282 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Change in Body Weight (%)

result −3.4 percent change (Change in Body Weight (%))

RCTNCT02964247Phase 3 · 2017 · n=303 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c

result −0.7 Percentage of HbA1c (Change in HbA1c)

RCTNCT02973321Phase 2 · 2016 · n=296 · Sanofi

Type 2 Diabetes Mellitus

tested Change From Baseline in HbA1c to Week 26

result −0.6 percentage of HbA1c (Change From Baseline in HbA1c to Week 26)

RCTNCT030106832015 · n=60 · University of Athens

Type 2 Diabetes Mellitus

tested Differences in Pulse Wave Velocity at Baseline and 3, 6 and 12 Months After Treatment With Metformin or Agonist GLP-1R.

result +0.6 m/s (Differences in Pulse Wave Velocity at Baseline and…)

RCTNCT03011008Phase 4 · 2017 · n=20 · Second Xiangya Hospital of Central South University

Type 1 Diabetes Mellitus

tested Mean amplitude of glycemic excursions (MAGE)

result In progress (unknown)

RCTNCT03011021Phase 1 · 2017 · n=40 · Second Xiangya Hospital of Central South University

Type1 Diabetes Mellitus

tested Adverse effects

result In progress (unknown)

RCTNCT03018028Phase 3 · 2017 · n=243 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c (Week 26)

result −1.2 Percentage point of HbA1c (Change in HbA1c (Week 26))

RCTNCT03034941Phase 4 · 2014 · n=35 · University Medical Centre Ljubljana

Obesity

tested The main outcome was change in BMI

result Completed; results not posted

RCTNCT03036800Phase 4 · 2017 · n=392 · University of Leicester

Obesity

tested Weight Loss of ≥15% From Baseline (Complete Cases)

result +45.0 Participants (Weight Loss of ≥15% From Baseline (Complete Cases))

RCTNCT03038620Phase 4 · 2017 · n=235 · University of Texas Southwestern Medical Center

Obesity, Visceral

tested Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI

result +10.9 percentage of reduction in VAT (Relative Percent Reduction in Visceral Adipose Tis…)

RCTNCT03041792Phase 1 · 2017 · n=61 · Pfizer

Obesity

tested Change From Baseline (Visit 3) in Mean Energy Intake During Ad Libitum Lunches at Visits 4 and 5

result −235 kilocalories (kcal) (Change From Baseline (Visit 3) in Mean Energy Inta…)

RCTNCT03048578Phase 4 · 2017 · n=132 · NYU Langone Health

Obesity

tested Percentage of Participants Losing at Least 5% Enrollment Body Weight Measured Using Cochran-Mantel-Haenszel (CMH) Test

result +59.0 percentage of participants (Percentage of Participants Losing at Least 5% Enro…)

RCTNCT03068065Phase 4 · 2014 · n=87 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

NAFLD / steatotic liver disease — hepatic fat reduction

tested Intrahepatic fat

result Completed; results not posted

RCTNCT03087032Phase 4 · 2019 · n=164 · The First Affiliated Hospital of Xiamen University

Type 2 Diabetes Patients

tested the proportion of patients with HbA1c < 7.0% without experiencing hypoglycemia and without weight gain,with a superiority margin of 3%

result In progress (recruiting)

RCTNCT03101930Phase 4 · 2017 · n=329 · Vanderbilt University Medical Center

Obesity

tested Change in Flow-mediated Dilation

RCTNCT03115099Phase 1 · 2017 · n=80 · Eli Lilly and Company

Diabetes Mellitus, Type 2

tested Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

result Completed; results not posted

RCTNCT03115424Phase 3 · 2017 · n=46 · Mayo Clinic

Obesity

tested Weight

result −3.0 kilograms (Weight)

RCTNCT03158805Phase 2 · 2017 · n=60 · Lindner Center of HOPE

Bipolar Disorder

tested Percent Change in Body Weight

result −3.5 % change (Percent Change in Body Weight)

RCTNCT03172494Phase 3 · 2017 · n=720 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c

RCTNCT03175120Phase 3 · 2017 · n=453 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c

result −0.9 Percentage point of HbA1c (Change in HbA1c)

RCTNCT03182426Phase 1 · 2017 · n=22 · University of Alberta

Diabetes Mellitus, Type 1

tested Change of 2-hour mixed meal stimulated C-peptide AUC

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT03191396Phase 3 · 2017 · n=577 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c

result +0.6 Percentage of glycosylated haemoglobin (Change in HbA1c)

RCTNCT03235050Phase 2 · 2017 · n=834 · AstraZeneca

Diabetes Mellitus, Type 2

tested Change in HbA1c

RCTNCT03260881Phase 4 · 2018 · n=38 · University of Miami

Type2 Diabetes

tested EAT Inflammation

result −0.7 ct (cycle threshold) (EAT Inflammation)

RCTNCT03279731Phase 3 · 2017 · n=36 · Kelly Allison

Binge-Eating Disorder

tested Binge Episodes

result −1.5 objective binge episodes per week (Binge Episodes)

Terminated: The study was not meeting recruitment goals.

RCTNCT03292185Phase 1 · 2017 · n=24 · Novo Nordisk A/S

Diabetes

tested Area under the serum insulin degludec concentration time curve

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT03341429Phase 4 · 2018 · n=70 · University College, London

Obesity

tested %WL

result Completed; results not posted

RCTNCT03347890Phase 4 · 2018 · n=70 · Zoltan Pataky

Obesity

tested Change of Bold Oxygenation Level Dependent (BOLD) signal (%) in brain regions involved in the reward system

result Completed; results not posted

RCTNCT03374956Phase 3 · 2017 · n=193 · Mayo Clinic

Obesity

tested Change in Total Body Weight

result −1.2 percent change (Change in Total Body Weight)

RCTNCT03421119Phase 3 · 2019 · n=300 · Cinnagen

Diabetes Mellitus, Type 2

tested HbA1c

result In progress (unknown)

RCTNCT03426085Phase 2 · 2016 · n=44 · Eastern Virginia Medical School

Autonomic Nervous System Diseases

tested Sudomotor Function

result In progress (unknown)

RCTNCT03449654Phase 4 · 2017 · n=102 · Steno Diabetes Center Copenhagen

Diabetes Mellitus, Type 2

tested Change in vascular inflammation

result Completed; results not posted

RCTNCT03466021Phase 4 · 2018 · n=40 · Claus Bogh Juhl

Pulmonary Disease, Chronic Obstructive

tested Transition Dyspnea Index (TDI)

result Completed; results not posted

RCTNCT03480022Phase 3 · 2018 · n=88 · Woman's

Pre Diabetes

tested Absolute Body Weight (BW)

result −13.2 kilogram (Absolute Body Weight (BW))

RCTNCT03486392Phase 2 · 2018 · n=474 · Janssen Research & Development, LLC

Obesity

tested Percent Change From Baseline in Body Weight at Week 26

result −5.8 Percent Change (Percent Change From Baseline in Body Weight at Wee…)

RCTNCT03500484Early Phase 1 · 2018 · n=13 · Yale University

Obesity, Childhood

tested Brain Response in Obese Young Adults Who Drink Sugar Sweetened Beverages.

result Terminated before completion

Terminated: The study was initially paused due to COVID restrictions and then when able to resume, there was no longer funding.

RCTNCT03523273Phase 2 · 2017 · n=136 · Michael Camilleri, MD

Obesity

tested Gastric Emptying of Solids (T1/2)

result +85.7 minutes (Gastric Emptying of Solids (T1/2))

RCTNCT03555994Phase 2 · 2018 · n=51 · MedImmune LLC

Type 2 Diabetes Mellitus

tested Change in Hepatic Glycogen Concentration Adjusted for Liver Volume as Measured by MRS at T = 4 Hours Post Standardised Morning Meal From Baseline (Day -1) to the End of 28 Days of Treatment (Part A Only)

result −106 mmol/L (Change in Hepatic Glycogen Concentration Adjusted …)

RCTNCT03619330Phase 4 · 2014 · n=30 · University Medical Centre Ljubljana

Hypogonadism

tested The main outcome was improvements of symptoms related to hypogonadism

result Completed; results not posted

RCTNCT03642600Phase 4 · 2019 · n=21 · Universitaire Ziekenhuizen KU Leuven

PCOS

tested weight loss

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT03671733Phase 3 · 2018 · n=150 · Xiangya Hospital of Central South University

Obesity

tested Weight Change at 3 months

result In progress (unknown)

RCTNCT03672812Phase 3 · 2018 · n=50 · Hospital de Clinicas de Porto Alegre

Brain Death

tested change inflammation

result Completed; results not posted

RCTNCT03712098Phase 2 · 2018 · n=40 · Rebecca Ashare

Smoking Cessation

tested Number of Participants With 7-day Point Prevalence Smoking Abstinence at 12 Weeks Post-Target Quit Date

result ±0.0 Participants (Number of Participants With 7-day Point Prevalence…)

RCTNCT03757130Phase 1 · 2018 · n=50 · Amgen

Obesity

tested Number of Participants With Treatment-emergent Adverse Events

result +6.0 Participants (Number of Participants With Treatment-emergent Adv…)

RCTNCT037957012019 · n=73 · Texas Tech University

Obesity

tested Compare the changes of pre-prandial fMRI-FCR in Liraglutide 3.0 vs. Placebo Group

result Completed; results not posted

RCTNCT03856047Phase 2 · 2019 · n=706 · Novo Nordisk A/S

Overweight

tested Change in Body Weight (%)

result −5.5 Percentage point of body weight (Change in Body Weight (%))

RCTNCT03856632Phase 4 · 2019 · n=60 · University of Miami

Atrial Fibrillation

tested Change in size of Left Atrial Epicardial Adipose Tissue (LAEAT)

result In progress (active-not-recruiting)

RCTNCT03883412Phase 4 · 2019 · n=60 · University of Virginia

Type2 Diabetes

tested Microvascular Blood Volume - change from baseline

result In progress (recruiting)

RCTNCT039483472019 · n=1708 · First Affiliated Hospital of Jinan University

Ischemic Stroke

tested Percentage of patients with the 90-day new stroke events (ischemic or hemorrhagic)

result In progress (unknown)

RCTNCT03955575Phase 4 · 2019 · n=52 · Filip Krag Knop

Bile Acid Malabsorption

tested Change in stool fequency

result Completed; results not posted

RCTNCT03986008Phase 3 · 2019 · n=60 · Xiangya Hospital of Central South University

Obesity

tested Weight Change at 3 months

result In progress (unknown)

RCTNCT04008290Phase 4 · 2020 · n=15 · Universitaire Ziekenhuizen KU Leuven

Obesity

tested MMC activity compared between placebo and treatment with liraglutide

result In progress (unknown)

RCTNCT04046822Phase 4 · 2019 · n=70 · Federico II University

Obesity

tested Change in gut microbiome composition assessed by Firmicutes-to-Bacteroidetes ratio using Quantitative polymerase chain reaction (PCR)

result In progress (unknown)

RCTNCT04057261Phase 3 · 2020 · RWTH Aachen University

Type 2 Diabetes

tested Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months

result Withdrawn before enrolment

Withdrawn: A study start is currently not foreseeable for organizational reasons. Due to the delays, research has also been focused on new compounds, which has reduced the interest in the potential results of the above-mentioned clinical trial.

RCTNCT04074161Phase 3 · 2019 · n=338 · Novo Nordisk A/S

Overweight

tested Change From Baseline (Week 0) to Week 68 in Body Weight (%) (Semaglutide 2.4 mg Versus Liraglutide 3.0 mg)

result +10.0 Percentage of body weight (Change From Baseline (Week 0) to Week 68 in Body W…)

RCTNCT04122716Phase 4 · 2016 · n=215 · Signe Torekov

Obesity

tested Body weight change (kg)

result In progress (unknown)

RCTNCT041373282019 · n=60 · Fudan University

Diabetic Neuropathic Pain

tested Numerical pain scale (NRS)

result In progress (unknown)

RCTNCT04146155Phase 4 · 2020 · n=200 · Second Affiliated Hospital, Zhejiang University, School of Medicine

Type 2 Diabetes

tested Initial and absolute claudication distance

result In progress (unknown)

RCTNCT041864942019 · n=30 · St Vincent's University Hospital, Ireland

Sleep Apnea, Obstructive

tested Insulin resistance

result Completed; results not posted

RCTNCT04199728Phase 1 · 2021 · n=27 · Milton S. Hershey Medical Center

Opiate Substitution Treatment

tested Change in Self-reported Cue-elicited Drug Craving as Measured by Visual Analog Scale (VAS)

result +8.3 score on a scale (Change in Self-reported Cue-elicited Drug Craving …)

Small sample; effect at the edge of clinical significance.

RCTNCT04311411Phase 1 · 2020 · n=114 · Eli Lilly and Company

Obesity

tested Change From Baseline in Calorie Intake in Participants Receiving Tirzepatide or Placebo at Week 3

result −534 kilocalories (kcal) (Change From Baseline in Calorie Intake in Particip…)

RCTNCT043242292020 · n=80 · Turku University Hospital

Gestational Diabetes

tested Incidence of type 2 diabetes

result In progress (active-not-recruiting)

RCTNCT04325581Phase 3 · 2016 · n=16 · Post Graduate Institute of Medical Education and Research, Chandigarh

Weight Loss

tested Incretin change

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT04373967Phase 3 · 2020 · n=424 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Type 2 Diabetes

tested glycated hemoglobin (HbA1c)

result In progress (unknown)

RCTNCT04487743Phase 3 · 2020 · n=300 · Xiangya Hospital of Central South University

Obesity

tested Mean Change From Baseline in Fasting Body Weight

result In progress (unknown)

RCTNCT04525300Phase 3 · 2020 · n=300 · Xiangya Hospital of Central South University

Obesity

tested The composition of the gut microbiota from baseline to end of treatment.

result In progress (unknown)

RCTNCT04531176Phase 4 · 2020 · n=74 · The Cleveland Clinic

Type 2 Diabetes

tested Mean Change in Body Weight Between Baseline and 12 Months

result Terminated before completion

Terminated: After an unplanned yet IRB approved interim analysis, it was found that there was not a significant difference between the 3 arms of the study. The study was closed due to futility. All Patients are off study and this study will not resume.

RCTNCT04535960Phase 2 · 2019 · n=36 · University Health Network, Toronto

Type 2 Diabetes Mellitus

tested Proximal tubular natriuresis

result In progress (unknown)

RCTNCT04575844Phase 4 · 2020 · n=80 · University of Virginia

Metabolic Syndrome

tested Microvascular Blood Volume - change from baseline

result In progress (recruiting)

RCTNCT04605861Phase 3 · 2020 · n=414 · Shanghai Zhongshan Hospital

Obese

tested The percentage of body weight loss

result Completed; results not posted

RCTNCT04657939Phase 4 · 2020 · n=57 · University of Leeds

Diabetes Mellitus, Type 2

tested Change in myocardial perfusion after treatment

result Completed; results not posted

RCTNCT04683237Phase 2 · 2021 · Xiaojun Chen

Atypical Endometrial Hyperplasia

tested Pathological complete response (CR) rates

result Withdrawn before enrolment

Withdrawn: Based on our latest research results, we will revise the protocol and design a better study. Since no participants are enrolled till now, we withdraw this study.

RCTNCT04763564Phase 2 · 2022 · n=8 · University of North Carolina, Chapel Hill

Pouchitis

tested Mean % Reduction of Bowel Frequency in Percent of the Mean 7-day Bowel Frequency After 4 Weeks of Therapy on Liraglutide vs Placebo Compared to Baseline .

result +19.0 percentage reduction of bowel frequency (Mean % Reduction of Bowel Frequency in Percent of …)

Terminated: Due to an interruption in drug supply, the study was terminated

RCTNCT04775082Phase 3 · 2021 · n=78 · Novo Nordisk A/S

Obesity

tested Relative change in BMI (Body mass index)

result In progress (active-not-recruiting)

RCTNCT048299032020 · n=116 · Corporacion Parc Tauli

Type 2 Diabetes Treated With Insulin

tested Glycemic level

result Completed; results not posted

RCTNCT04881110Phase 4 · 2021 · n=60 · University of Campania Luigi Vanvitelli

Type 2 Diabetes

tested Peripheral Transcutaneous Oxygen Pressure

result +10.8 mmHg (Peripheral Transcutaneous Oxygen Pressure)

RCTNCT04903509Phase 1 · 2021 · n=95 · Boehringer Ingelheim

Pharmacokinetic / healthy volunteer studies

tested Percentage of subjects with drug-related adverse events

result Completed; results not posted

RCTNCT05029076Phase 1 · 2019 · n=28 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Type 2 Diabetes

tested Maximum (peak) plasma drug concentration(Cmax)

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

RCTNCT05111912Phase 2 · 2021 · n=206 · Sciwind Biosciences APAC CO Pty. Ltd.

Obesity

tested Percentage change in participants body weight (%) from the Baseline

result Completed; results not posted

RCTNCT05225974Phase 1 · 2021 · n=32 · The Affiliated Hospital of Qingdao University

Therapeutic Equivalency

tested Peak Plasma Concentration (Cmax)

result Completed; results not posted

RCTNCT05268237Phase 1 · 2023 · n=15 · Biolingus

Diabete Type 2

tested Incidence, nature and severity of adverse events

result In progress (recruiting)

RCTNCT052686272022 · n=38 · Mansoura University

Obesity

tested weight loss

result In progress (unknown)

RCTNCT052853972022 · n=60 · General Committee of Teaching Hospitals and Institutes, Egypt

Morbid Obesity

tested Percentage Total weight loss

result In progress (unknown)

RCTNCT05294536Phase 1 · 2020 · n=50 · Sunshine Lake Pharma Co., Ltd.

Type 2 Diabetes

tested Maximum (peak) plasma drug concentration(Cmax)

result Completed; results not posted

RCTNCT053135292022 · n=396 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Cognitive function in aging

tested Mild cognitive impairment (MCI) remission rate

result Completed; results not posted

RCTNCT05360147Phase 3 · 2021 · n=30 · Third Military Medical University

Type 2 Diabetes Mellitus

tested Changes in cognitive function from baseline to 12 weeks

result Completed; results not posted

RCTNCT05360537Phase 4 · 2021 · n=100 · University of Palermo

Diabetes Mellitus, Type 2

tested Change of Time in Range % at 7 days, at 1 and 6 months

result Completed; results not posted

RCTNCT053903072023 · n=60 · Dasman Diabetes Institute

Type 1 Diabetes

tested Weight

result Completed; results not posted

RCTNCT05444569Phase 1 · 2022 · n=47 · Eli Lilly and Company

Pharmacokinetic / healthy volunteer studies

tested Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

result Completed; results not posted

RCTNCT05579249Phase 4 · 2023 · n=500 · Novo Nordisk A/S

Obesity

tested Number of Participants Who Achieved Greater Than or Equal to (≥) 10.0 Percent (%) Body Weight Reduction (Yes/no)

RCTNCT05681299Phase 4 · 2023 · n=40 · Columbia University

Pharmacokinetic / healthy volunteer studies

tested AgRP change in GH vs. placebo arms

result In progress (recruiting)

RCTNCT057053882023 · n=50 · Emirates Health Services (EHS)

Obesity

tested Mean percent total body weight loss at 6 months in each arm of the study

result In progress (unknown)

RCTNCT05767255Phase 3 · 2022 · n=66 · Hospital Universitario San Ignacio

Diabetes Mellitus, Type 2 Treated With Insulin

tested To compare the percentage of hypoglycemia

result In progress (unknown)

RCTNCT057796442023 · n=300 · RenJi Hospital

NAFLD / steatotic liver disease — hepatic fat reduction

tested Blood glucose

result In progress (unknown)

RCTNCT05794581Phase 1 · 2023 · n=32 · Carmot Therapeutics, Inc.

Type 1 Diabetes

tested To assess area under the curve (AUC) in glucose metabolism during MMTT

result Completed; results not posted

RCTNCT05952882Phase 3 · 2023 · n=188 · Mỹ Đức Hospital

Polycystic Ovary Syndrome

tested Absolute Body Weight (BW)

result In progress (unknown)

RCTNCT05965908Phase 3 · 2024 · n=183 · Beni-Suef University

Polycystic Ovary

tested Insulin Resistance (HOMA-IR)

result Completed; results not posted

RCTNCT06171152Early Phase 1 · 2024 · n=30 · University of Chicago

Multiple Sclerosis

tested Change from Baseline in Serum Brain Derived Neurotrophic Factor (BDNF) after 8 Weeks

result In progress (terminated)

RCTNCT06361238Phase 3 · 2024 · n=260 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Delirium, Postoperative

tested The incidence of delirium

result In progress (recruiting)

RCTNCT06449703Phase 1 · 2024 · n=44 · Tonghua Dongbao Pharmaceutical Co.,Ltd

Pharmacokinetic / healthy volunteer studies

tested Maximum observed plasma insulin degludec concentration

result In progress (unknown)

RCTNCT06501326Phase 4 · 2023 · n=102 · Affiliated Hospital of Nantong University

NAFLD / steatotic liver disease — hepatic fat reduction

tested Body weight

result In progress (unknown)

RCTNCT06559722Phase 3 · 2024 · n=510 · Tonghua Dongbao Pharmaceutical Co.,Ltd

Type 2 Diabetes

tested Change from baseline in HbA1c after 26 weeks of treatment

result In progress (unknown)

RCTNCT06742710Phase 4 · 2025 · n=890 · Peking University Third Hospital

PCOS

tested Live birth rate associated with single cycle frozen embryo transfer

result In progress (recruiting)

RCTNCT068362842026 · n=40 · Karolinska Institutet

Childhood Obesity

tested Change in BMI SDS

result In progress (recruiting)

RCTNCT06865365Phase 4 · 2025 · n=72 · Medical University of Vienna

Obesity, Adolescent

tested % total weight loss

result In progress (recruiting)

RCTNCT06976619Phase 2 · 2025 · n=60 · Mayo Clinic

Type 1 Diabetes

tested Effect of exendin 9-39 on fasting glucagon secretion rate before and after liraglutide treatment

result In progress (recruiting)

RCTNCT07244003Phase 4 · 2025 · n=430 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

T2DM (Type 2 Diabetes Mellitus)

tested The change of HbA1c compared to the baseline

result In progress (recruiting)

RCTNCT07301437Phase 4 · 2026 · n=120 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Overweight and Obese Adults

tested weight loss

result In progress (recruiting)

RCTNCT07590219Phase 4 · 2024 · n=30 · University of Sao Paulo General Hospital

Severe Obesity

tested Change in Body Mass Index (BMI)

result In progress (active-not-recruiting)

RCTPMID 16026367n=210

Treatment studies

tested HbA1c change and weight change

result Weight change –0.05 to –1.9%; HbA1c change +0.22% to +0.30% for liraglutide 0.45–0.75 mg, comparable to metformin (+0.09%).

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

RCTPMID 19947303

Treatment studies

tested blood glucose control

result Liraglutide demonstrated efficacy and safety in the LEAD programme compared with placebo and other antidiabetic therapies.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

RCTPMID 27337846

Treatment studies

tested weight loss

result Controlled SCALE trials showed liraglutide 3.0 mg improves weight loss in obese patients.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

RCTPMID 37707701n=300

Treatment studies

tested change in HbA1c

result Mean HbA1c change was -1.76% (SD 1.22) with Melitide vs -1.59% (SD 1.31) with Victoza; mean difference -0.18 (95% CI -0.5 to 0.15) meeting non‑inferiority margin.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

RCTPMID 39192527n=68

Treatment studies

tested C‑peptide area under the curve (AUC) after 52 weeks

result After 52 weeks, 4‑hour C‑peptide AUC was maintained with liraglutide but decreased with placebo (P=.002); total daily insulin dose fell from 0.30 to 0.23 U/kg/day vs rose from 0.29 to 0.43 U/kg/day (P<.001).

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

RCTPMID 41871584n=40

Treatment studies

tested Apnea-Hypopnea Index

result Liraglutide reduced AHI by -9.87 events/h (95% CI -19.5 to -0.247, p=0.044) and ODI by -10.16 events/h (95% CI -19.29 to -1.03, p=0.029) versus placebo.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

OpenNCT00873223Phase 1 · 2009 · n=33 · Novo Nordisk A/S

Diabetes

tested Insulin detemir pharmacokinetics with and without liraglutide administration

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

ObseNCT012121332010 · n=1386 · Novo Nordisk A/S

Diabetes

tested The number of serious adverse drug reactions (SADRs) during the study period

result Completed; results not posted

ObseNCT012269662010 · n=3152 · Novo Nordisk A/S

Diabetes

tested Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%

result Completed; results not posted

ObseNCT012883262011 · n=254 · Novo Nordisk A/S

Diabetes

tested Percentage of participants with a decrease in HbA1c (glycosylated haemoglobin A1c) of at least 1%

result Completed; results not posted

ObseNCT012990122010 · n=30 · University at Buffalo

Type 1 Diabetes Mellitus

tested Improved Blood Glucose comtrol in Type 1 Diabetes Patients with Liraglutide

result Completed; results not posted

ObseNCT013457342011 · n=1056 · Novo Nordisk A/S

Diabetes

tested Incidence of serious adverse drug reactions (SADRs)

result Completed; results not posted

ObseNCT014030252011 · n=4121 · Novo Nordisk A/S

Diabetes

tested The incidence of SADRs (Serious Adverse Drug Reactions)

result Completed; results not posted

ObseNCT014842622011 · n=1344 · Novo Nordisk A/S

Diabetes

tested Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life)

result Completed; results not posted

OpenNCT01499108Phase 4 · 2012 · n=32 · Peter Rossing

Type 2 Diabetes

tested Change in ambulatory blood pressure

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT01507337Phase 1 · 2004 · n=32 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Area under the liraglutide plasma concentration time curve (AUC 0-t)

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT01507389Phase 1 · 2006 · n=24 · Novo Nordisk A/S

Diabetes

tested Area under the Curve (0-infinity)

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT01508806Phase 1 · 2005 · n=30 · Novo Nordisk A/S

Diabetes

tested Area under the Curve (AUC)

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT01509755Phase 2 · 2000 · n=196 · Novo Nordisk A/S

Diabetes

tested HbA1c (glycosylated haemoglobin)

result Completed; results not posted

OpenNCT01517568Phase 1 · 2006 · n=7 · Novo Nordisk A/S

Pharmacokinetic / healthy volunteer studies

tested Profile and identity of the major metabolites of tritium labelled liraglutide in plasma, urine, and faeces

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT01542242Phase 4 · 2012 · n=1 · Vancouver General Hospital

Diabetes Mellitus Type 2

tested Hemoglobin A1C

result Terminated before completion

Terminated: Subject withdrew

OpenNCT015753012011 · n=411 · University of Dundee

Diabetes

tested Change in HbA1c between baseline and 6 months

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT015993382011 · n=30 · Centre Hospitalier Universitaire Dijon

Type 2 Diabetes Mellitus

tested Change in liking and wanting for protein, lipid and glucid foods

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

ObseNCT018218462013 · n=64 · Novo Nordisk A/S

Diabetes

tested The incidence of SADRs (Serious Adverse Drug Reactions)

result Completed; results not posted

OpenNCT01832532Phase 1 · 2013 · n=34 · Children's Hospital Medical Center, Cincinnati

Sleep Apnea

tested Change in Apnea Hypopnea Index (AHI) From Baseline

result +4.2 apnea / hypopnea events per hour sleep (Change in Apnea Hypopnea Index (AHI) From Baseline)

Non-randomised; effect size cannot be separated from placebo.

OpenNCT01856790Early Phase 1 · 2013 · n=15 · Jennifer Sherr

Type 1 Diabetes

tested Peak Post-prandial Venous Glucose Levels

result −22.0 mg/dL (Peak Post-prandial Venous Glucose Levels)

Non-randomised; effect size cannot be separated from placebo.

ObseNCT018909932013 · n=952 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c (glycosylated haemoglobin)

result Completed; results not posted

ObseNCT020779462014 · n=1059 · Novo Nordisk A/S

Diabetes

tested Percent (%) of patients achieving at least 1 %-point HbA1c (glycosylated haemoglobin) reduction

result Completed; results not posted

OpenNCT02082496Phase 2 · 2014 · n=50 · University of Copenhagen

Obesity

tested Difference in insulin levels in reponse to GLP-1 RA treatment in obese genetic mutation carriers vs obese controls

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT02089256Phase 4 · 2014 · n=10 · University of Tartu

Pharmacokinetic / healthy volunteer studies

tested Change in the glucose-sensitivity of the beta cells

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT02198209Phase 4 · 2019 · Cedars-Sinai Medical Center

Type 2 Diabetes

tested Liver glucokinase activity (acute effect)

result Withdrawn before enrolment

Withdrawn: Investigator decided not to move forward with study prior to study start date

ObseNCT022552662015 · n=1788 · Novo Nordisk A/S

Diabetes

tested Frequency of patients achieving HbA1c reduction of at least 1%-point

result Completed; results not posted

ObseNCT023218782014 · n=1092 · Novo Nordisk A/S

Diabetes

tested Number of AEs (adverse events)

result Completed; results not posted

OpenNCT02516657Phase 3 · 2012 · n=5 · University at Buffalo

Type 1 Diabetes

tested Mean Weekly Blood Glucose

Non-randomised; effect size cannot be separated from placebo.

OpenNCT02535299Phase 4 · 2016 · n=200 · Third Military Medical University

GLP-1；Metformin；Telomere-telomerase System；Par-4

tested physiological parameter:glycosylated hemoglobin A1c

result In progress (unknown)

Non-randomised; effect size cannot be separated from placebo.

OpenNCT02602600Phase 4 · 2015 · n=33 · Eva Prescott

Microvascular Angina

tested Change from baseline in Coronary Flow Reserve

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT02616003Phase 4 · 2014 · n=50 · Sana Klinikum Offenbach

Morbid Obesity

tested Operability

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT02654665Phase 3 · 2014 · n=36 · Changi General Hospital

NAFLD / steatotic liver disease — hepatic fat reduction

tested Improvement in NASH

result In progress (unknown)

Non-randomised; effect size cannot be separated from placebo.

OpenNCT02674893Phase 4 · 2014 · n=48 · Centre Hospitalier Universitaire Dijon

Type 2 Diabetes

tested Modifications in wanting

result Terminated before completion

Terminated: Exploratory protocol, convincing results, robust analysis

OpenNCT02718950Phase 3 · 2016 · n=20 · University of Campinas, Brazil

Obesity

tested Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans

result In progress (unknown)

Non-randomised; effect size cannot be separated from placebo.

OpenNCT02721888Phase 4 · 2012 · n=127 · Centre Hospitalier Universitaire Dijon

Type 2 Diabetes

tested Effect of liraglutide on fatty liver content evaluated by proton-spectroscopy (1H-spectroscopy and lipoprotein kinetics, in patients with type 2 diabetes

result Terminated before completion

Terminated: Failure of inclusion

OpenNCT02743598Phase 4 · 2016 · n=4 · Temple University

HIV-associated lipodystrophy — visceral fat reduction

tested Neurocognitive performance- change in global cognitive scores on a standard neuropsychological profile

result Terminated before completion

Terminated: Lack of funding and time

ObseNCT027548172016 · n=611 · Novo Nordisk A/S

Diabetes

tested Change in HbA1c (Hemoglobin A1c)

result Completed; results not posted

ObseNCT027733552016 · n=27 · Novo Nordisk A/S

Obesity

tested Frequency of pancreatitis

result Completed; results not posted

Small sample; effect at the edge of clinical significance.

OpenNCT02920190Phase 4 · 2020 · University of Miami

Monoclonal Gammopathies

tested Change in Epicardial Fat Thickness

result Withdrawn before enrolment

Withdrawn: Lack of funds to cover the costs of the study medications

ObseNCT029677572016 · n=316 · Novo Nordisk A/S

Metabolism and Nutrition Disorder

tested Number of patients with BMI above or equal to 30 kg/m^2

result Completed; results not posted

ObseNCT030707042017 · Novo Nordisk A/S

Diabetes

tested Incidence of treatment emergent Adverse Events (AEs)

result Withdrawn before enrolment

Withdrawn: Request for the study waived by Indian Health Authorities

OpenNCT03371862Phase 2 · 2017 · Imperial College London

Short Bowel Syndrome

tested Improvement in parenteral support

result Withdrawn before enrolment

Withdrawn: No participants recruited. Not able to recruit due to COVID 19.

ObseNCT034797622018 · n=105 · Novo Nordisk A/S

Obesity

tested Number of patients with a BMI above or equal to 30 kg/m^2 (Saxenda® only)

result Completed; results not posted

OpenNCT035200622017 · n=14 · Nicolai Jacob Wewer Albrechtsen

Obesity

tested Volumetric Changes of the Pancreas

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT035343102015 · n=75 · Catholic University of the Sacred Heart

Obesity

tested Change of baseline BMI

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

ObseNCT035603362018 · n=758 · Novo Nordisk A/S

Obesity

tested Incidence of adverse events (AEs) by preferred term (PT)

result Completed; results not posted

OpenNCT03632759Early Phase 1 · 2018 · n=16 · Carla Greenbaum, MD

Type 1 Diabetes Mellitus

tested Proportion of individuals with peak MMTT stimulated C-peptide >0.017 pmol/mL.

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT03707171Phase 3 · 2018 · n=30 · Third Military Medical University

Type 2 Diabetes Mellitus

tested Changes of cognitive function assessed by cognitive function scale after 12 weeks.

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

ObseNCT038233392019 · n=300 · Novo Nordisk A/S

Diabetes Mellitus, Type 2

tested Change in laboratory measured glycosylated haemoglobin A1c (HbA1c)

result Completed; results not posted

ObseNCT038852972019 · n=43 · University Hospitals Coventry and Warwickshire NHS Trust

Overweight

tested Weight changes related to treatment

result Completed; results not posted

ObseNCT038881572019 · n=839 · Novo Nordisk A/S

Diabetes Mellitus, Type 2

tested Change in glycated haemoglobin A1c (HbA1c) (percentage)

result Completed; results not posted

ObseNCT039360492017 · n=168690 · Brigham and Women's Hospital

Diabetes

tested Relative hazard of composite outcome of Stroke, MI, and Mortality

result Completed; results not posted

ObseNCT039931322018 · n=26774 · Boehringer Ingelheim

Diabetes Mellitus, Type 2

tested Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis

result −0.2 Events per 1000 person-years (Incidence Rate of Expanded Major Adverse Cardiovas…)

OpenNCT04529278Phase 2 · 2021 · n=18 · Fondation Hôpital Saint-Joseph

Diabetes Mellitus, Type 2

tested Weight Loss at Week 26

result In progress (unknown)

Non-randomised; effect size cannot be separated from placebo.

OpenNCT04575194Phase 4 · 2020 · n=40 · National and Kapodistrian University of Athens

Obesity

tested Changes in blood pressure

result In progress (unknown)

Non-randomised; effect size cannot be separated from placebo.

OpenNCT046433012020 · Zuyderland Medisch Centrum

Obesity

tested %TWL (%TWL)

result Withdrawn before enrolment

Withdrawn: Cancellation by sponsor

ObseNCT046669872020 · n=359 · Novo Nordisk A/S

Diabetes Mellitus, Type 2

tested Change in Glycated Haemoglobin (HbA1c)

result Completed; results not posted

OpenNCT04781998Phase 4 · 2021 · n=24 · Anders Fink-Jensen, MD, DMSci

Mental Disorder

tested The primary endpoint is the number of "completers"

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT04839237Phase 2 · 2017 · Xiangya Hospital of Central South University

Obesity

tested Weight Change at 3 months

result Withdrawn before enrolment

Withdrawn: The sponsor decides withdrawn this study.

OpenNCT04883346Phase 2 · 2021 · n=34 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Obesity

tested Cohen's d (the Standardized Mean Difference)

Non-randomised; effect size cannot be separated from placebo.

ObseNCT049527792021 · n=750 · Novo Nordisk A/S

Diabetes Mellitus, Type 2

tested Incidence of Adverse Events (AEs) by preferred term

result Completed; results not posted

ObseNCT050736922021 · n=241981 · Kaiser Permanente

Type 2 Diabetes Mellitus

tested Incidence of 3-point Major Adverse Cardiovascular Events (MACE)

ObseNCT051535902021 · n=269 · Novo Nordisk A/S

Obesity or Overweight

tested Relative change in body weight greater than or equal to 5% (lower BMI with weight related comorbidities) or greater than or equal to 7% (higher BMI) in reimbursed setting (yes/no)

result Completed; results not posted

ObseNCT051621832019 · n=3474 · Brigham and Women's Hospital

Diabetes

tested Relative Hazard of change in HbA1c from baseline to 26 weeks of treatment (end of follow-up)

result Completed; results not posted

ObseNCT052212292022 · n=29 · University Hospital Birmingham

Atrial Fibrillation

tested Adherence to Liraglutide by AF patients before and after first-time ablation [Time Frame- 13 weeks before and 52 weeks after ablation]

result In progress (active-not-recruiting)

ObseNCT054381862022 · Novo Nordisk A/S

Obesity

tested Relative change in body weight

result Withdrawn before enrolment

Withdrawn: No participants enrolled since study start.

OpenNCT05467514Phase 3 · 2022 · n=35 · David Sanchez Garcia

Diabetes Mellitus, Type 1

tested To assess the effect of liraglutide on carotid intima media thickness in patients with type 1 diabetes mellitus.

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

ObseNCT057567642023 · n=30 · Louisiana State University Health Sciences Center in New Orleans

Obesity

tested weight loss

result In progress (active-not-recruiting)

ObseNCT060990672020 · n=239990 · AstraZeneca

Type 2 Diabetes Mellitus

tested 3-point MACE

result Completed; results not posted

OpenNCT06201819Phase 4 · 2022 · n=37 · Hospital Civil Juan I. Menchaca

Weight Loss

tested Preoperative weight changes

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT06217848Early Phase 1 · 2022 · n=50 · Seoul National University Hospital

Panhypopituitarism

tested Change in weight

result In progress (unknown)

Non-randomised; effect size cannot be separated from placebo.

ObseNCT062836412024 · n=300 · Novo Nordisk A/S

Obesity

tested Incidence of adverse events (AEs) by preferred term (PT)

result Completed; results not posted

OpenNCT06438146Phase 4 · 2024 · n=40 · Brigham and Women's Hospital

HIV-associated lipodystrophy — visceral fat reduction

tested Proportion of participants who screen and enroll among those approached

result In progress (unknown)

Non-randomised; effect size cannot be separated from placebo.

OpenNCT06439056Phase 1 · 2024 · n=12 · Nanexa AB

Type 2 Diabetes

tested To evaluate the PK profile of liraglutide after single ascending doses of NEX-22A in subjects with stable type 2 diabetes

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

OpenNCT07029009Phase 2 · 2025 · n=50 · Mansa

Maturity Onset Diabetes of the Young

tested Blood sugar control - HbA1C

result In progress (recruiting)

Non-randomised; effect size cannot be separated from placebo.

OpenNCT07225816Phase 1 · 2025 · n=71 · Novo Nordisk A/S

Obesity

tested Occurrence of empty stomach (antrum grade 0 or 1) after fasting following a solid, high-fat meal after dosing of subcutaneous (s.c.) liraglutide once daily (Yes/No)

result In progress (recruiting)

Non-randomised; effect size cannot be separated from placebo.

OpenNCT07374445Phase 4 · 2023 · n=100 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Obesity

tested Change in %TWL from baseline to endpoint across patient groups

result Completed; results not posted

Non-randomised; effect size cannot be separated from placebo.

CasePapern=1

Treatment studies

tested weight loss, reduced BMI, improved HbA1c

result BMI decreased from 34 kg/m2 to 27.4 kg/m2 and HbA1c fell from 11.6% to 7.5% after liraglutide therapy.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CrosPMID 11812750n=11

Treatment studies

tested fasting plasma glucose and postprandial glucose AUC

result Fasting glucose reduced to 6.9 ± 1.0 vs 8.1 ± 1.0 mmol/L (P=0.004); postprandial glucose AUC decreased to 30.6 ± 2.4 vs 39.9 ± 7.3 mmol·L⁻¹·h⁻¹ (P<0.001).

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

StudPMID 20857706

Treatment studies

tested glycated haemoglobin reduction

result Reduced glycated haemoglobin by ≥1% in type 2 diabetes patients; also caused moderate weight loss and mild blood pressure reduction.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

StudPMID 27180668

Treatment studies

tested glycated hemoglobin reduction

result decreasing glycated hemoglobin up to 15 mmol/l

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

CrosPMID 33584289n=38

Diagnostic & mechanistic studies

tested Pharmacokinetic similarity (AUC, Cmax) between biosimilar and reference

result GMRs were 113.5% for Cmax, 107.2% for AUC0‑t, and 107.0% for AUC0‑∞, all 90% CIs within 80‑125% equivalence range.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 38643826

Treatment studies

tested body weight reduction and glycaemia improvement

result Saxenda was effective at reducing body weight and glycaemia in people with obesity and diabetes.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 42164611n=20096

Treatment studies

tested Barrett's esophagus without dysplasia

result Barrett's esophagus without dysplasia occurred in 0.3% of sleeve gastrectomy patients vs 0.1% of liraglutide patients (RR 2.70, 95% CI 1.31-5.56).

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

OpenPMID 42203210n=40

Treatment studies

tested weight, waist circumference, HbA1c, depression, sleep quality, quality of life

result Weight decreased by 2.9% (range -1.0 to -4.5%); waist circumference reduced by 5.6 cm (−8.2 to −2.9); HbA1c fell by 0.3% (−0.4 to −0.2).

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

ObsePMID 42210885

Treatment studies

tested one‑month postoperative inflammatory complications (infection, wound disruption, hematoma, etc.)

result GLP cohort associated with a significantly reduced risk of infection after a procedure, wound disruption, skin/subcutaneous infection, hematoma, and other complications compared with patients without GLP use.

Published human study (PubMed / Europe PMC), extracted from its abstract — not a CT.gov-registered trial.

AnimalPMID 11679431

Preclinical / mechanistic research

tested rat · Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 12217892

Preclinical / mechanistic research

tested mouse · The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 14678021

Preclinical / mechanistic research

tested rat · The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 25556713

Preclinical / mechanistic research

tested mouse · Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 32495167

Preclinical / mechanistic research

tested mouse · Intranasal Human Recombinant Modified Glucagon-Like Peptide-1: High Antihyperglycemic Activity and Duration of Action in Mice.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 41856344

Preclinical / mechanistic research

tested rat · Glucagon-like peptide-1 analog, liraglutide, alters blood-testis barrier permeability in juvenile healthy rats.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 41863197

Preclinical / mechanistic research

tested rat · Therapeutic potential of liraglutide in rheumatoid arthritis: Modulation of inflammation, apoptosis, and metabolic dysfunction in a rat model.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 42147332

Preclinical / mechanistic research

tested rat · GLP-1 agonist liraglutide decreases operant methamphetamine intake in rats under conditions of short- but not extended-access to the drug.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 42193161

Preclinical / mechanistic research

tested rat · Liraglutide Modifies Gut Microbiota Without Modulating Doxorubicin-Induced Toxicity in Rats.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 42341385

Preclinical / mechanistic research

tested rat · Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 42377486

Preclinical / mechanistic research

tested rat · Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

AnimalPMID 42505368

Preclinical / mechanistic research

tested rat · Changes in the Adrenal Cortex Induced by Liraglutide Treatment and Exercise in a Rat Model of Menopausal Transition.

result Preclinical publication captured from PubMed/Europe PMC; effect details require paper-level extraction.

In vitroPMID 42549609

Preclinical / mechanistic research

tested Liraglutide reprograms vascular smooth muscle cell metabolism to suppress extracellular matrix remodeling in diabetic atherosclerosis.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 42589634

Preclinical / mechanistic research

tested Semaglutide and Liraglutide Modulate Oxidative Stress and Wound Repair in Normal Human Skin Cells Exposed to an In Vitro Diabetic-like Environment.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

In vitroPMID 42695487

Preclinical / mechanistic research

tested Liraglutide Attenuates Hepatocyte Ferroptosis in an In Vitro Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.

result In-vitro publication captured from PubMed/Europe PMC; assay details require paper-level extraction.

Anecdotal efficacy

Weight loss & appetite control

About three‑quarters of users say liraglutide helped them lose weight for many, describing losses of 40‑60+ pounds over several months and reduced appetite. A smaller share reports mixed results, while a notable minority finds it ineffective.

1-4 of 155

+“I’m 6 months in (24 weeks) and down just shy of 50 lbs.”r/liraglutide · 2 upvotes +“I lost weight for over 2 months on the starting dose of .6 mg.”r/liraglutide · 2 upvotes +“I have been on 1.2 for almost 3 months. I originally planned to go up to a regular dosage but got really sick when I increased it from 1.2 tot 1.8.”r/liraglutide · 2 upvotes +“Just about done with my 23rd week (not quite 6 months) and down 47 lbs, starting at 230 lbs.”r/liraglutide · 2 upvotes

Liraglutide side effects

Clinical research side effects

Anecdotal side effects

Side effect source data

3829 linked sources are available across clinical rows and community reports.

Clinical 3602Anecdotal 227

1-6 of 3829

ClinicalNausea / GI

Nausea — 6.6%NCT02730377 · Liraglutide 1.8 mg (n=980)

ClinicalOther

Acute kidney injury — <1%NCT02730377 · Liraglutide 1.8 mg (n=980) · Serious adverse event

ClinicalOther

Acute myocardial infarction — <1%NCT02730377 · Liraglutide 1.8 mg (n=980) · Serious adverse event

ClinicalOther

Angina pectoris — <1%NCT02730377 · Liraglutide 1.8 mg (n=980) · Serious adverse event

ClinicalOther

Cerebrovascular accident — <1%NCT02730377 · Liraglutide 1.8 mg (n=980) · Serious adverse event

ClinicalOther

Chest pain — <1%NCT02730377 · Liraglutide 1.8 mg (n=980) · Serious adverse event

Price

Full buying guide →

1

CertapeptidesCode AFF-GROUNDTRUTH

10 mg

$31.40

$3.14/mg

2

Genesis Peptides

USA

5 mg

$39.00

$7.8/mg

3

Kensington Labs

10 mg

$93.82

$9.38/mg

4

Aminousa

5 mg

$51.00

$10.2/mg

5

bgpharmadrugs.to

6 mg

$85.00

$14.17/mg

6

Peptides World

5 mg

$99.00

$19.8/mg

price offers can be sorted by column · 1 out-of-stock offer not shown

Some links are affiliate links. This never affects our rankings or inclusion.

1-6 of 7

Liraglutide dosing & protocol

How Liraglutide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials

Published clinical-trial protocols · n = 334

Typical dose

1.8 mg600 µg – 6 mg

typical

0
mg
mg
mg

distribution of 174 reported doses · darker = more

Frequency: daily
Route: subQ

Trials used subcutaneous liraglutide most often at 1.8 mg once daily, though doses ranged from 0.6 mg to 6 mg per day and weight‑based regimens of 5–20 µg/kg were also reported.

334 sources

Clinician practice

Doctor & published-protocol guidance · n = 2

Typical dose

1.8 mg600 µg – 3 mg

typical

0
mg
mg
mg

distribution of 4 reported doses · darker = more

By reported cadence· tap a row to filter the chart

Frequency: daily
Route: subQ

In clinical practice, liraglutide is given subcutaneously once daily at doses ranging from 0.6 mg to 1.8 mg, while a minority use twice‑daily 3 mg injections.

2 sources

Anecdotal

Community-reported real-world use · n = 21

Typical dose

1.2 mg300 µg – 6 mg

typical

0
mg
mg
mg

distribution of 24 reported doses · darker = more

Frequency: unspecified
Route: subQ

Community reports cite a typical liraglutide dose of 1.2 mg subcutaneously, ranging from 0.3 mg to 6 mg; only one source noted daily dosing, and no cycling regimen was mentioned.

21 sources

Dose & protocol sources

357 linked sources are available across the research, clinician, and community tiers. Each card states what that source says, with a link to it.

Research trials 334Clinician practice 2Anecdotal 21

Research trialsNCT01179048

Dose 1.8 mgFrequency daily

Time From Randomisation to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)

NCT01179048 · Phase 3 ↗

Research trialsNCT02730377

Dose 1.8 mg

Time to Inadequate Glycaemic Control

NCT02730377 · Phase 4 ↗

Research trialsNCT01336023

Mean Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 26.

NCT01336023 · Phase 3 ↗

Research trialsNCT01836523

Dose 0.6 mgFrequency daily

Change From Baseline in HbA1c (Glycosylated Haemoglobin)

NCT01836523 · Phase 3 ↗

Research trialsNCT00318461

Dose 0.6 mg

Change in Glycosylated A1c (HbA1c) at Week 26

NCT00318461 · Phase 3 ↗

Research trialsNCT02501161

Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification

NCT02501161 · Phase 3 ↗

1-6 of 357

Regulatory safety notes

Warnings and precautions

• Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including liraglutide injection. Discontinue if pancreatitis is suspected.
• Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated.
• Hypoglycemia: Can occur in adults when liraglutide injection is used with an insulin secretagogue (e.g. a sulfonylurea) or insulin. The risk may be lowered by a reduction in the dose of concomitantly administered insulin secretagogues or insulin. In the pedia…
• Heart Rate Increase: Monitor heart rate at regular intervals.
• Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.
• Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. Liraglutide injection is not recommended in patients with severe gastroparesis.
• Hypersensitivity Reactions: Postmarketing reports of serious hypersensitivity reactions (e.g., anaphylactic reactions and angioedema) . Discontinue liraglutide injection and other suspect medications and promptly seek medical advice.
• Pulmonary Aspiration During General Anesthesia or Deep Sedation : Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedu…

Contraindications

• Patients with a personal or family history of medullary thyroid carcinoma (MTC) or
• patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1) ] .
• Patients with a serious hypersensitivity reaction to liraglutide or to any of the excipients in liraglutide injection. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reporte…

Drug interactions

• Liraglutide injection delays gastric emptying. May impact absorption of concomitantly administered oral medications. Use with caution. (7)

Related peptides

Semaglutide Tirzepatide Retatrutide Survodutide AOD-9604 Cagrilintide Orforglipron Exenatide Tesamorelin Eloralintide Tesofensine Mazdutide

Liraglutide

Research Evidence

Endpoint-classified outcomes.

What has been tested in people.

Animal and in-vitro context.

Papers behind this peptide.

Every row behind the score.

Anecdotal efficacy

Weight loss & appetite control

Liraglutide side effects

Side effect source data

Price

Liraglutide dosing & protocol

Dose & protocol sources

Regulatory safety notes

Related peptides